Zimmer Biomet Holdings, Inc. $ZBH Position Reduced by Ballentine Partners LLC

Ballentine Partners LLC reduced its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 3.7% in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 3,648 shares of the medical equipment provider’s stock after selling 140 shares during the quarter. Ballentine Partners LLC’s holdings in Zimmer Biomet were worth $333,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Garde Capital Inc. bought a new position in Zimmer Biomet during the first quarter valued at about $29,000. Washington Trust Advisors Inc. acquired a new stake in Zimmer Biomet in the 1st quarter valued at about $30,000. Columbia River Financial Group LLC bought a new position in shares of Zimmer Biomet during the 1st quarter valued at about $30,000. Accent Capital Management LLC acquired a new position in shares of Zimmer Biomet in the 1st quarter worth approximately $35,000. Finally, Cullen Frost Bankers Inc. raised its holdings in shares of Zimmer Biomet by 1,452.4% in the 1st quarter. Cullen Frost Bankers Inc. now owns 326 shares of the medical equipment provider’s stock worth $37,000 after purchasing an additional 305 shares in the last quarter. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Zimmer Biomet news, SVP Lori Winkler sold 1,500 shares of the company’s stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $104.15, for a total value of $156,225.00. Following the transaction, the senior vice president directly owned 6,833 shares of the company’s stock, valued at $711,656.95. This represents a 18.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.70% of the stock is owned by company insiders.

Analyst Ratings Changes

ZBH has been the subject of a number of research reports. Stifel Nicolaus raised their target price on shares of Zimmer Biomet from $115.00 to $118.00 and gave the stock a “buy” rating in a report on Friday, September 19th. Royal Bank Of Canada increased their price objective on Zimmer Biomet from $112.00 to $115.00 and gave the company an “outperform” rating in a research report on Friday, August 8th. Rothschild Redb raised Zimmer Biomet to a “strong-buy” rating in a research note on Thursday, September 18th. Evercore ISI cut their target price on Zimmer Biomet from $102.00 to $96.00 and set an “in-line” rating on the stock in a research report on Tuesday, July 8th. Finally, Raymond James Financial upped their target price on Zimmer Biomet from $104.00 to $113.00 and gave the company an “outperform” rating in a report on Friday, August 8th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, seven have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $113.16.

Zimmer Biomet Stock Up 1.2%

Shares of Zimmer Biomet stock opened at $98.18 on Monday. Zimmer Biomet Holdings, Inc. has a 1 year low of $89.22 and a 1 year high of $114.72. The company has a market cap of $19.45 billion, a P/E ratio of 23.89, a P/E/G ratio of 2.26 and a beta of 0.68. The company has a current ratio of 1.87, a quick ratio of 0.96 and a debt-to-equity ratio of 0.54. The stock has a 50-day moving average price of $100.58 and a 200 day moving average price of $99.07.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share for the quarter, beating the consensus estimate of $1.98 by $0.09. The company had revenue of $2.08 billion for the quarter, compared to analysts’ expectations of $2.06 billion. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The business’s revenue for the quarter was up 7.0% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.01 EPS. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. As a group, analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be given a dividend of $0.24 per share. The ex-dividend date of this dividend is Tuesday, September 30th. This represents a $0.96 dividend on an annualized basis and a yield of 1.0%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 23.36%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.